<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884556</url>
  </required_header>
  <id_info>
    <org_study_id>TTX-030-001</org_study_id>
    <nct_id>NCT03884556</nct_id>
  </id_info>
  <brief_title>TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers</brief_title>
  <official_title>Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or Chemotherapy in Patients With Lymphoma or Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trishula Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trishula Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity,&#xD;
      leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of&#xD;
      immunosuppressive adenosine, which may change the tumor microenvironment and promote&#xD;
      anti-tumor immune response.&#xD;
&#xD;
      This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of&#xD;
      TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and&#xD;
      standard chemotherapies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>1 cycle (each cycle is 21-28 days)</time_frame>
    <description>Assess the safety profile, dose limiting toxicity (DLT), maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of TTX-030 when administered intravenously (IV) as a single agent and in combination with agents in specified regimens to subjects with advanced solid tumor malignancies or lymphoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Anti-tumor activity in subjects treated with TTX-030 as single agent or in combination with specified regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Cycles 1-3 (each cycle is 21-28 days)</time_frame>
    <description>Pharmacokinetics (PK) of TTX-030</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD39 Expression</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Pharmacodynamic (PD) biomarkers relating to mechanism of action and immune responses</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm 1, Single Agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2, Anti-PD-1 Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3, Chemotherapy Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4, Chemotherapy Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTX-030 plus gemcitabine plus nab-paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTX-030</intervention_name>
    <description>Variable dose and schedule</description>
    <arm_group_label>Arm 1, Single Agent</arm_group_label>
    <arm_group_label>Arm 2, Anti-PD-1 Combination</arm_group_label>
    <arm_group_label>Arm 3, Chemotherapy Combination</arm_group_label>
    <arm_group_label>Arm 4, Chemotherapy Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Dose and schedule per standard of care</description>
    <arm_group_label>Arm 2, Anti-PD-1 Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Dose and schedule per standard of care</description>
    <arm_group_label>Arm 3, Chemotherapy Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Dose and schedule per standard of care</description>
    <arm_group_label>Arm 4, Chemotherapy Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab paclitaxel</intervention_name>
    <description>Dose and schedule per standard of care</description>
    <arm_group_label>Arm 4, Chemotherapy Combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Abreviated Inclusion Criteria&#xD;
&#xD;
          1. Advanced solid tumor malignancy or relapsed/refractory lymphoma, or&#xD;
&#xD;
               -  eligible to receive single-agent pembrolizumab as standard of care, or&#xD;
&#xD;
               -  eligible to receive single-agent docetaxel as standard of care, or&#xD;
&#xD;
               -  advanced pancreatic adenocarcinoma and eligible to receive gemcitabine plus&#xD;
                  nab-paclitaxel as standard of care.&#xD;
&#xD;
          2. Age 18 years or older, is willing and able to provide informed consent&#xD;
&#xD;
          3. Evidence of measurable disease&#xD;
&#xD;
          4. Life expectancy &gt; 12 weeks and Eastern Cooperative Oncology Group (ECOG) performance&#xD;
             status of 0-1&#xD;
&#xD;
        Abbreviated Exclusion Criteria&#xD;
&#xD;
          1. History of allergy or hypersensitivity to study treatment components. Patients with a&#xD;
             history of severe hypersensitivity reaction to any monoclonal antibody.&#xD;
&#xD;
          2. Use of investigational agent within 28 days prior to the first dose of study treatment&#xD;
             and throughout the study&#xD;
&#xD;
          3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive&#xD;
             therapy&#xD;
&#xD;
          4. History of severe autoimmune disease&#xD;
&#xD;
          5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trishula Therapeutics, Inc.</last_name>
    <phone>+1 888-480-0554</phone>
    <email>clinicaltrials@trishulatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Irvine Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothy Chang</last_name>
      <phone>714-509-2199</phone>
      <email>dorothc@hs.uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Joo</last_name>
      <phone>916-734-4913</phone>
      <email>ssjoo@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Immunotherapy program</last_name>
      <email>HDFCCC.CIP@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Fernandez, CCRC</last_name>
      <phone>305-243-2647</phone>
      <email>i.fernandez6@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Studies</last_name>
      <phone>312-CANCER-1</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Orem</last_name>
      <phone>502-629-2500</phone>
      <phone_ext>19471</phone_ext>
      <email>ben.orem@nortonhealthcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Adkisson, RN</last_name>
      <phone>502-629-2500</phone>
      <phone_ext>19460</phone_ext>
      <email>pamela.adkisson@nortonhealthcare.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Center Oncology Hematology West P.C.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Meays, M.A. CCRC</last_name>
      <phone>402-691-6971</phone>
      <email>mmeays@nebraskacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Kovalenko</last_name>
      <phone>973-972-3173</phone>
      <email>kovaleoa@cinj.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Ghalib</last_name>
      <phone>718-405-8515</phone>
      <email>mhghalib@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Sanjay Goel, MD</last_name>
      <phone>718-405-8404</phone>
      <email>sgoel@montefiore.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Information Services</last_name>
      <phone>800-641-2422</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Cancer Center and Research Institute</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Fletcher</last_name>
      <phone>901-683-0055</phone>
      <email>afletcher@westclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Referral Line</last_name>
      <phone>615-329-7478</phone>
      <email>Cann.researchreferrals@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Intitute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Leary, RN, BSN</last_name>
      <phone>801-213-8429</phone>
      <email>ashley.leary@hci.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 16, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Metastatic Solid Tumors</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Relapsed/Refractory Lymphoma</keyword>
  <keyword>Prostrate Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Monotherapy</keyword>
  <keyword>Combination Therapy</keyword>
  <keyword>CD39</keyword>
  <keyword>Adenosine Pathway</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>PD-1</keyword>
  <keyword>Checkpoint Inhibitor</keyword>
  <keyword>Nab-paclitaxel</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

